Evidence map›Paper›PMID 41481938›Full record

ArticleACS chemical biology2026

Quantitative Degradation Rate Assessment of bioPROTACs Based on Peptide Degrons, E3 Domains, Adapters and Conjugated Small Molecules.

David Vukovic, Dorothea Winkelvoß, Anto Udovcic, Luca Riermeier, Saul Jaime-Figueroa, Craig M Crews, Andreas Plückthun

Abstract read
In one paragraph

Article in ACS chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Reductive Methylation: An Alternative to Lysine → Arginine Mutagenesis.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David VukovicDepartment of Biochemistry, University of Zurich, Zurich 8057, Switzerland.
Dorothea WinkelvoßDepartment of Biochemistry, University of Zurich, Zurich 8057, Switzerland.
Anto UdovcicDepartment of Biochemistry, University of Zurich, Zurich 8057, Switzerland.
Luca RiermeierDepartment of Biochemistry, University of Zurich, Zurich 8057, Switzerland.
Saul Jaime-FigueroaDepartments of Molecular, Cellular and Developmental Biology; Chemistry; Pharmacology, Yale University, New Haven, Connecticut 06520-8103, United States.
Craig M CrewsDepartments of Molecular, Cellular and Developmental Biology; Chemistry; Pharmacology, Yale University, New Haven, Connecticut 06520-8103, United States.ORCID 0000-0002-8456-2005
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zurich 8057, Switzerland.ORCID 0000-0003-4191-5306

Funding

Inducing Proximity: An Emerging Paradigm for New Therapeutic ModalitiesR35CA197589 · NCI · YALE UNIVERSITY · PI CRAIG M CREWS · 2015 to 2026
$10.7M
NCI NIH HHS R35 CA197589
6 · The paper itself

Abstract

Protein-based bispecific degraders, known as bioPROTACs, have emerged as powerful tools for targeted protein degradation through the ubiquitin-proteasome system (UPS). However, the relative efficacy of various recruitment domains within these degraders remains poorly understood. To address this knowledge gap, we conducted a comprehensive comparison of recruitment domains in bioPROTACs, utilizing eGFP as a proof-of-principle degradation target and an eGFP-binding DARPin with known structure as an adapter. Our innovative approach combined microinjection and live-cell microscopy, enabling a detailed assessment of directly measured degradation rates as a single-cell kinetic readout, unaffected by uptake or biosynthesis rates of the degrader, and across the different chemical classes. We examined nine degron peptides, three E3 ligase domains or adapters, and two series of small-molecule binders, linked in various geometries. Our results revealed that bioPROTACs based on E3 or adapter protein domains and small molecules generally exhibited the highest degradation rates, while most degron peptides showed comparatively low efficacy. Notably, for VHL-ligand-1 and thalidomide, the placement of the coupling site and linker position significantly influenced performance. This study provides crucial insights into the design and optimization of bioPROTACs, paving the way for the development of more effective degraders for specific applications. Our findings contribute to the growing field of targeted protein degradation and offer valuable guidance for researchers seeking to enhance the efficacy of bioPROTAC-based therapeutic approaches.

Indexed as

PeptidesProteolysisSmall Molecule LibrariesUbiquitin-Protein LigasesDegronsGreen Fluorescent ProteinsHumansProtein Domainsenhanced green fluorescent proteinGreen Fluorescent ProteinsPeptidesSmall Molecule LibrariesUbiquitin-Protein Ligases

Identifiers

PMID41481938
PMCPMC12813978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.